Skip to content
2000
Volume 2, Issue 4
  • ISSN: 1573-3971
  • E-ISSN: 1875-6360

Abstract

The antiphospholipid syndrome (APS) is characterised by arterial and/or venous thrombosis and pregnancy morbidity in the presence of anticardiolipin antibodies (aCL) and/or lupus anticoagulant (LA). APS can occur either as a primary disorder (PAPS) or secondary to a connective tissue disease, more frequently systemic lupus erythematosus (SLE). Any organ and any size of vessel can be affected in this disorder. In 1983 Hughes, in his original description of the syndrome, also reported thrombocytopenia, neurological disease, livedo reticularis and labile hypertension. The range of clinical features that has been associated with the presence of antiphospholipid antibodies (aPL) is extremely wide and has broadened over the last 20 years.

Loading

Article metrics loading...

/content/journals/crr/10.2174/157339706778699779
2006-11-01
2025-05-06
Loading full text...

Full text loading...

/content/journals/crr/10.2174/157339706778699779
Loading

  • Article Type:
    Research Article
Keyword(s): anticardiolipin antibodies; Cerebral disease; lupus anticoagulant; thrombosis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test